Company intelligence / Profile preview
Revotar Biopharmaceuticals
Hennigsdorf, Brandenburg, Germanyrevotar.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Revotar’s lead candidate, bimosiamose—a pan-selectin antagonist—has completed several Phase I and IIa clinical trials in asthma, COPD, and psoriasis. Results have shown a good safety and efficacy profile in nearly 200 patients and volunteers. The company has also reported positive top-line results from a Phase II trial with inhaled bimosiamose for respiratory diseases such as COPD. Additional preclinical programs are focused on other anti-inflammatory targets.
- Therapeutic areas
- PulmonologyDermatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Texas Biotechnology Corporation/TBCoUndisclosed US pharma partner
Beyond the preview
Go deeper on Revotar Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Revotar Biopharmaceuticals.